ARIAD Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 5 Calls Today's Calls

Call Details ARIAD Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009) Thu, Nov 5, 2009, 8:30 am Eastern Listen to the archived event audio About ARIAD Pharmaceuticals, Inc. (NasdaqGM:ARIA) ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe. Its product candidates include deforolimus, a potent mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, leukemias, and lymphomas; and AP24534, a multi-targeted kinase inhibitor for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and other hematological cancers. ARIAD conducts Phase 3 clinical trials of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas; Phase 2 clinical trials in patients with endometrial, breast, and prostate cancers; and Phase 1 studies of deforolimus in combination with other agents, as well as Phase 1 clinical trials of AP24534 in patients with refractory CML, AML, and other hematological malignancies. Its drug discovery programs are centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. In addition, the company licenses NF-kB cell-signaling technology and treatment methods to pharmaceutical and biotechnology companies conducting research to discover and develop drugs that modulate NF-kB cell-signaling and/or marketing such drugs; and ARGENT cell-signaling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products and to conduct drug discovery research. It has a collaboration agreement with Merck & Co., Inc. to develop and commercialize deforolimus; and license agreements with Medinol and ICON to develop and commercialize deforolimus-eluting stents and other medical devices to prevent restenosis, or reblockage of injured vessels following interventions, in which stents are used in conjunction with balloon angioplasty. The company was founded in 1991 and is based in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings